At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Ipatasertib (drug), Tiragolumab (drug), Atezolizumab (drug), Tiragolumab and Atezolizumab (drug)
- How long the study runs
- Study runs about 117 months (dates as stated)
- About the drug or intervention
- Ipatasertib — drug: Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study. · Tiragolumab — drug: Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study. · Atezolizumab — drug: Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study. · Tiragolumab and Atezolizumab — drug: Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study. · Bevacizumab — drug: Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study. · Entrectinib — drug: Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study. · Inavolisib — drug: Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study. · Divarasib — drug: Divarasib will be administered as a monotherapy or in combination with atezolizumab or bevacizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- Not specified
- Who
- All
- Number of participants
- 100
- Started
- 2023-06-01
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for cancer
- • Phase3 - 100 participants
- • The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally
Who can take part?
- • Adults
- • Diagnosed with cancer
Where?
- • Leicester - Leicester Royal Infirmary
- • Surrey - Royal Marsden Hospital - Surrey
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Cancer
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: Not specified
- Who can join: All genders
What the study is looking for
- ✓Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent...
- ✓Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study...
- ✓First dose of study treatment in this extension study will be received within 7 days of the treatment interruption...
- ✓Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as...
- ✓Ability to comply with the extension study protocol, per Investigator's judgement
Who cannot take part
- ✗Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in...
- ✗Study treatment or comparator agent is commercially marketed in the participant's country for the...
- ✗Concurrent participation in any therapeutic clinical trial (other than the parent study)
See the full criteria
Inclusion Criteria:
* Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR
* Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
* First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study
* Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator
* Ability to comply with the extension study protocol, per Investigator's judgement
Exclusion Criteria:
* Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study
* Study treatment or comparator agent is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant
* Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this extension study
* Permanent discontinuation of all study treatment(s) or comparator agent(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this extension study (if applicable)
* Ongoing SAE(s) that has not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in this extension study
* Concurrent participation in any therapeutic clinical trial (other than the parent study)
Where Is This Study? (2 UK sites)
Leicester Royal Infirmary
Leicester LE1 5WW, United Kingdom
Hospital R&D contact (matched)
Carolyn Maloney
uhl-tr.researchandinnovationadminmailbox@nhs.net0116 258 8351Royal Marsden Hospital - Surrey
Surrey SM2 5PT, United Kingdom
How to Get in Touch
Reference Study ID Number: BX44273 https://forpatients.roche.com/ No attachments to email below.
Sponsor contactCONTACT
888-662-6728 (U.S. Only) global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Sponsor contactCONTACT
Data sourced from ClinicalTrials.gov · Last verified: 2026-10